Kirby McInerney LLP is investigating potential claims against the Board of Directors of ViroPharma Incorporated (“ViroPharma” or the “Company”) (NASDAQ:VPHM) concerning the proposed acquisition of the Company by Shire plc (“Shire”). Under the terms of the proposed transaction, ViroPharma stockholders will receive $50.00 in cash for each share of ViroPharma owned, valuing the transaction at approximately $4.2 billion.

The investigation concerns whether the ViroPharma Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the $50.00 per share proposed consideration adequately values ViroPharma’s common stock.

If you are a ViroPharma stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, stockholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

Copyright Business Wire 2010